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NAPVSIPQ (NAP), an active fragment of the glial-derived activity-
dependent neuroprotective protein, is protective at femtomolar
concentrations against a wide array of neural insults and prevents
ethanol-induced fetal wastage and growth retardation in mice.
NAP also antagonizes ethanol inhibition of L1-mediated cell adhe-
sion (ethanol antagonism). We performed an Ala scanning substi-
tution of NAP to determine the role of ethanol antagonism and
neuroprotection in NAP prevention of ethanol embryotoxicity. The
Ser-Ile-Pro region of NAP was crucial for both ethanol antagonism
and protection of cortical neurons from tetrodotoxin toxicity
(neuroprotection). Ala replacement of either Ser-5 or Pro-7 (P7A-
NAP) abolished NAP neuroprotection but minimally changed the
efficacy of NAP ethanol antagonism. In contrast, Ala replacement
of Ile-6 (I6A-NAP) caused a decrease in potency (>2 logarithmic
orders) with only a small reduction (<10%) in the efficacy of NAP
neuroprotection but markedly reduced the efficacy (50%) and the
potency (5 logarithmic orders) of NAP ethanol antagonism. Ethanol
significantly reduced the number of paired somites in mouse
whole-embryo culture; this effect was prevented significantly by
100 pM NAP or by 100 pM P7A-NAP, but not by 100 pM I6A-NAP.
The structure–activity relation for NAP prevention of ethanol
embryotoxicity was similar to that for NAP ethanol antagonism
and different from that for NAP neuroprotection. These findings
support the hypothesis that NAP antagonism of ethanol inhibition
of L1 adhesion plays a central role in NAP prevention of ethanol
embryotoxicity and highlight the potential importance of ethanol
effects on L1 in the pathophysiology of fetal alcohol syndrome.
Fetal alcohol syndrome (FAS) is the most common prevent-able cause of mental retardation (1). Ethanol has multiple
cellular targets in the nervous system (2); hence, it is not
surprising that it damages the fetus through a variety of mech-
anisms: oxidative injury, induction of apoptosis, suppression of
neurogenesis, disruption of cell–cell interactions, and alterations
in the release and signaling of growth factors, morphogens, and
chemical messengers (3–10). Several drugs that block specific
molecular actions of ethanol have been shown to prevent or
mitigate ethanol’s teratogenesis in animal models (11, 12), an
unexpected finding, given the complex pathophysiology of FAS.
Delineating the mechanism of action of these drugs would help
to identify the most critical mechanisms that underlie ethanol’s
teratogenesis.
Brain lesions in children with FAS resemble those of children
with mutations in the gene for the L1 cell adhesion molecule,
suggesting that ethanol might perturb fetal development in part
by disrupting the actions of L1 (7). Interestingly, ethanol potently
inhibits L1-mediated cell–cell adhesion (7, 13, 14) and L1-
mediated neurite extension (15). A series of straight, cyclic, and
branched alcohols shows unexpectedly strict structural require-
ments for alcohol inhibition of cell adhesion, consistent with a
ligand-receptor interaction (16). Several alcohols proved to be
competitive or noncompetitive antagonists of ethanol inhibition
of L1 adhesion (17), and one such molecule, 1-octanol, also
prevented ethanol-induced dysmorphology and apoptosis in
mouse whole-embryo culture (11). These findings highlight the
potential importance of ethanol’s actions on L1 in the patho-
physiology of FAS and raise the possibility of identifying safe
ethanol antagonists.
A second class of compounds also prevents ethanol terato-
genesis (12). NAPVSIPQ (NAP) and SALLRSIPA (SAL) are
small peptide fragments of the glial-derived activity-
dependent neuroprotective protein (ADNP) and activity-
dependent neurotrophic factor (ADNF), respectively (18, 19).
Both NAP and SAL are protective at femtomolar concentra-
tions in vitro against the neural toxicity of a wide range of
compounds and cellular insults (18, 20, 21). NAP and SAL are
also neuroprotective in vivo against diverse neural insults,
including excitotoxicity (22), closed head injury (23), ischemic
brain injury (24), apoplipoprotein E deficiency (19), exposure
to the cholinotoxin ethylcholine aziridium (25), and prenatal
ethanol exposure (12). The precise mechanism by which NAP
and SAL produce neuroprotection is not clear, although a
variety of biochemical actions may contribute. NAP, SAL, or
their parent compounds increase levels of cGMP and nitric
oxide (26), promote the release of neurotrophic factor-3 (27),
induce the expression of heat shock protein 60 (20), activate
protein kinase C and mitogen-associated protein kinase kinase
(28), increase NF-B DNA-binding activity (29), protect
against oxidative injury, and reduce neuronal apoptosis (21,
24, 30, 31). Protection against oxidative injury may partly
explain NAP prevention of ethanol teratogenesis, be-
cause NAP decreases ethanol-induced depletion of reduced
glutathione (12).
We recently showed (32) that NAP and SAL potently antag-
onize ethanol inhibition of L1 adhesion. This observation raises
the question of whether NAP and SAL, like 1-octanol, prevent
ethanol embryotoxicity by antagonizing a specific action of
ethanol, rather than through broad neuroprotective actions. To
answer this question, we identified derivatives of NAP that
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differentially affect ethanol inhibition of L1 adhesion and pro-
tection against tetrodotoxin (TTX) neurotoxicity and tested
these for prevention of ethanol embryotoxicity. Electrical block-
ade with TTX was chosen as a model system to study neuro-
protection because of its relevance to activity-dependent mech-
anisms of neuronal development as well as its first use in
characterizing ADNP, the parent protein of NAP (19).
Methods
Materials. Ethanol was purchased from Fisher Scientific; all other
chemicals were purchased from Sigma-Aldrich (St. Louis) or as
indicated. Peptides were purchased from Peptide Technologies
(Washington, DC), Sigma Genosys (The Woodlands, TX), and
New England Peptides (Fitchburg, MA). Purity (95%)
and identity were assessed by these companies by using HPLC
and MS analyses. The peptides were dissolved in 10% DMSO in
PBS (0.13 M NaCl0.003 M KCl0.01 M Na2HPO40.002 M
KH2PO4) and stored as 1-mM aliquots. NAP was stable in
solution and could be aliquoted and frozen for later use without
loss of activity.
Culture of L1-Expressing NIH 3T3 Cells. NIH 3T3 cells were cultured
in DMEM supplemented with 10% normal calf serum and 400
gml G418 (all from Life Technologies, Rockville, MD). Two
subclones were used in these studies: 2A2-L1 and Vec-1A5. The
2A2-L1 cell line is an ethanol-sensitive subclone derived from a
stable transfection of NIH 3T3 cells with the human L1 cDNA,
and Vec-1A5 is a subclone from a transfection with the empty
expression vector (14). Both cell lines were cultured at 37°C, in
an atmosphere of 90% air and 10% CO2.
Cell Adhesion Assay. Cell–cell adhesion was measured by using a
short-term aggregation assay of subconfluent cells (32). Cells
were detached by gentle agitation with calcium-free and mag-
nesium-free PBS supplemented with 2 mM EDTA and 0.1
mgml DNase, mechanically dissociated to obtain a single-cell
suspension, and diluted to 330,000 cellsml. One ml of the cell
suspension was added per well (4.5 cm2) to a 12-well plate.
Peptides and ethanol were mixed together before their addition
to the cells, which were then mixed gently for 30 min on ice. Cells
were viewed at a final magnification of 200 and each well was
scored for single and adherent cells in five or six microscopic
fields of view. We counted 150–200 cells per field of view and
750–1,200 cells per well. The percentage of adherent cells was
calculated for each microscopic field of view and averaged. To
ensure the reliability of the cell adhesion assays, most assays were
scored without knowledge of the experimental conditions.
We define L1-mediated cell–cell adhesion (L1 adhesion) as
the difference in the percent of adherent cells between an
L1-expressing cell line (2A2-L1) and a vector-transfected cell
line (Vec-1A5). In L1-transfected cells, this component of cell
adhesion is fully inhibited by Fab fragments of an anti-L1
polyclonal antibody (7, 14, 33). Ethanol inhibition of cell adhe-
sion was calculated as 100  (1  the ratio of L1 adhesion in the
presence and absence of ethanol). We define antagonists as
compounds that alone have no effect on L1 adhesion, but block
the ethanol inhibition of L1 adhesion. Antagonist activity was
calculated as 100  1  [(percent inhibition of cell adhesion by
ethanol plus peptide)(percent inhibition of cell adhesion by
ethanol alone)].
Assay of TTX Toxicity in Neuronal Cells. Dissociated cerebral cortical
tissue from newborn rats was seeded on a confluent layer of
astroglial cultures derived from rat cerebral cortex (34). We
plated 250,000 cells into a 35-mm dish in a volume of 1.5 ml. The
mixed cultures were maintained in medium (35) consisting of 5%
horse serum in MEM supplemented with defined medium
components (36) and 9-fluoro-2-deoxyuridine (15 gml) plus
Fig. 1. Structure–activity relation for NAP antagonism of ethanol inhibition
of L1 adhesion. Adhesion assays were carried out in the absence and presence
of 100 mM ethanol and the indicated peptides, by using NIH 3T3 cells stably
transfected with human L1 cDNA (2A2-L1). Antagonist activity was calculated
as described (see Methods), based on the ability of each peptide to decrease
ethanol inhibition of L1-mediated cell adhesion. Alanine-scanning substitu-
tion produced seven NAP-derived peptides, which are named for the single-
letter amino acid that is replaced with Ala and its position with respect to the
N terminus (e.g., S5A, Ala replaces Ser-5 in NAP). Dose–response curves are
shown as follows: NAP, S5A, I6A, and P7A (A); NAP, N1A, and V4A (B); and NAP,
P3A, and Q8A (C). The NAP dose–response curve is reproduced in each figure
to facilitate comparison with the NAP mutants. Shown are the mean  SEM
values for antagonist activity derived from 3–15 independent experiments.
Mean values for adhesion were 39.1  0.8% in the absence of ethanol and
25.7  0.8% in the presence of ethanol. Some of the data points in the NAP
dose–response curve were taken from a previous publication (32) but were
derived contemporaneously with the Ala-substituted NAP derivatives.
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uridine (3 gml). The mixed cultures were 95% astrocytes.
Four days after adding the cerebral cortical suspension to
astrocyte feeder cultures, the culture preparations were given a
complete change of medium (before peptide treatment). Pep-
tides and 1 M TTX were added once and cultures were assayed
for neuronal survival after a 4-day incubation period. Neuronal
cell counts were conducted after fixation with glutaraldehyde
(35). Neuronal identity was established with sister cultures
immunocytochemically stained with antiserum against neuron-
specific enolase (37). Neurons were counted in 20 fields in each
culture dish without knowledge of the treatment group. Previous
studies demonstrated that 1 M TTX blocked synaptic activity
in CNS cultures (38) and produced decrements as measured with
many neuronal parameters, including choline acetyltransferase,
tetanus toxin fixation, saxitoxin binding (39) and neuronal
survival (40).
Whole-Embryo Culture. On gestational day 8, C57BL6J embryos
were explanted under a dissecting microscope with removal of
the maternal decidua, trophoblast, parietal yolk sac, and
Reichert’s membranes, whereas the visceral yolk sac, ectopla-
cental cone, and amnion remained intact (4). Those embryos
having three to five somite pairs were used for culture. Each
embryo was placed into a 30-ml vial containing 2.5 ml of medium
(75% heat-inactivated rat serum, 25% Tyrode’s solution). The
vials were flushed with a mixture of 5% O2, 5% CO2, and 90%
N2 and attached to a rotating wheel in an incubator maintained
at 37°C. Explanted embryos were exposed to experimental
agents for 6 h only, followed by culture for an additional 20 h in
control medium. Extraembryonic membranes were removed and
the embryos were examined under a dissecting microscope,
without knowledge of treatment condition, for morphological
assessment, and to allow determination of the number of somite
pairs. Each embryo was cultured separately, constituting an
independent experiment.
Operational Definitions. The ability of NAP to antagonize ethanol
inhibition of L1-mediated cell adhesion is referred to as NAP
antagonism. NAP protection of cortical neurons from TTX
toxicity is referred to as NAP neuroprotection. NAP prevention
of ethanol-induced reductions in somite number is referred to as
NAP prevention of ethanol embryotoxicity.
Statistical Analysis. By using STATVIEW software, the differences
among means of groups were analyzed by ANOVA. Multiple
comparison post-tests between groups were conducted by using
BonferroniDunn comparisons.
Results
Structure–Activity Relation for NAP Antagonism. L1-mediated cell
adhesion was measured in NIH 3T3 cells stably transfected with
human L1. Ethanol (100 mM) inhibited L1-mediated cell adhe-
sion and NAP completely antagonized this action of ethanol, as
reported (32). The dose–response curve for NAP revealed a
monophasic curve of antagonist activity over many logarithmic
orders, with half-maximal effects at 36 fM (Fig. 1).
Alanine scanning substitution produced seven NAP-derived
peptides, which are named for the single-letter amino acid that
is replaced by Ala and its position with respect to the N terminus
(e.g., S5A-NAP, Ala replaces Ser-5 in NAP). Dose–response
curves were determined for this series of NAP-derived peptides.
The Ala substitutions had strikingly different effects on NAP
antagonism (Fig. 1 and Table 1). Ala substitutions at the Ser-5
(S5A), Ile-6 (I6A), and Pro-7 (P7A) positions reduced both the
efficacy and potency of NAP. Of these three amino acids, Ile-6
was the most sensitive to Ala substitution. Compared with NAP,
the potency of I6A-NAP was reduced by 19,000-fold and its
efficacy was reduced by half. The efficacies of S5A-NAP (79%)
and P7A-NAP (77%) were reduced slightly compared with
NAP, but their potencies were decreased 500-fold and 1,400-
fold, respectively. In contrast, Ala substitution for the Asn
residue at the N-terminal position of NAP (N1A-NAP) had the
least effect, producing only a slight reduction in antagonist
potency and efficacy. Likewise, Ala substitutions at the Pro-3,
Val-4, and Gln-8 positions affected antagonist efficacy mini-
mally, whereas the dose–response curves for all three peptides
showed marked rightward shifts. These data define a structure-
activity relation in which the Ser-Ile-Pro (SIP) region of NAP is
important for antagonizing ethanol inhibition of L1 adhesion,
with Ile being a critical site.
Structure–Activity Relation for NAP Neuroprotection. A structure–
activity-relation analysis was performed for the neuroprotective
action of NAP on cortical neurons exposed to TTX (Fig. 2 and
Table 1). Four days of treatment with 1 M TTX reduced
neuronal survival by 37  2%. NAP potently and completely
prevented TTX neurotoxicity. The dose–response curve for
NAP neuroprotection showed two major peaks of activity with
potencies (EC50) of 0.003 fM and 3 pM. Ala substitution at the
Ser-5 and Pro-7 positions abolished the neuroprotective activity
of NAP. In contrast, Ala substitution at the Ile-6 position caused








P1 P2 P1 EC50, fM P2 EC50, pM
NAPVSIPQ (NAP) 97  4 (14) 100  2 97  4 36 0.003 3
AAPVSIPQ (N1A) 88  4 (5)* 89  3 101  3 69 0.1 100
NAAVSIPQ (P3A) 92  6 (3) 95  2 89  2* 46,000 100 300
NAPASIPQ (V4A) 92  2 (7)** 95  2 96  4 90,000 3 3
NAPVAIPQ (S5A) 79  8 (10)* 0*** 0*** 19,000 — —
NAPVSAPQ (I6A) 53  10 (15)*** 91  1* 91  2* 700,000 3 3,000
NAPVSIAQ (P7A) 77  5 (15)*** 0*** 0*** 50,000 — —
NAPVSIPA (Q8A) 93  7 (5) 97  1 98  2 4,400 0.003 3
NAP potency and efficacy were estimated from dose–response curves for NAP antagonism of ethanol inhibition of L1 adhesion (Fig.
1) and NAP protection of neuronal cultures from TTX toxicity (Fig. 2). NAP potency for ethanol antagonism was calculated from linear
regression analysis of the average values in the dose–response curves (n  3–15). NAP potency for neuroprotection was estimated from
the two peaks (P1 and P2) of the dose–response curves shown in Fig. 2 (n  3). L1, NAP antagonism of ethanol inhibition of L1 adhesion.
TTX, NAP protection of cortical neurons from TTX toxicity. *, P  0.05; **, P  0.01; ***, P  0.001 on paired t tests comparing efficacy
of NAP derivatives to NAP.

















a rightward shift in both peaks (2 logarithmic orders) of the
dose–response curve and only a small reduction (10%) in
efficacy for the higher affinity peak. Ala substitution at Asn-1,
Val-4, and Glu-8 did not reduce neuroprotective efficacy, and
among these three mutants, only N1A-NAP showed a modest
(33-fold) reduction in potency. Ala substitution at the Pro-3
position reduced the neuroprotective potency of NAP by 4.5
logarithmic orders, without reducing efficacy at the high-affinity
peak. The low-affinity peak of P3A-NAP showed a 2-logarithmic-
orders decrease in potency and an 11% decrease in efficacy
compared with that of NAP. These data demonstrate that the
SIP region of NAP is also critical for neuroprotection; however,
in this action, the Ser-5 and Pro-7 sites are much more sensitive
than the Ile-6 site.
NAP Prevention of Ethanol Embryotoxicity. Whole-embryo culture
allows the controlled administration of drugs and ethanol in the
absence of maternal influences, including nutritional variables.
At these early stages of embryogenesis, exposure to teratogenic
concentrations of ethanol in vivo, as well as in vitro (whole-
embryo culture), yields comparable results, including excessive
apoptotic cell death, neural tube defects, and craniofacial ab-
normalities (4, 11, 41, 42). We exploited the differences in
structure–activity relation for NAP antagonism and NAP neu-
roprotection to ask which action contributes to NAP prevention
of ethanol embryotoxicity. A single concentration (100 pM) of
NAP, I6A-NAP, and P7A-NAP was tested for prevention of
ethanol-induced growth retardation in mouse whole-embryo
culture. This concentration was chosen for its ability to produce
nearly maximal effects with NAP and markedly different effects
for the NAP derivatives. Gestational day 8 mouse embryos (3–5
somites) were cultured for 6 h in the absence or presence of 100
mM ethanol or peptide plus ethanol and then transferred to
control medium for an additional 20 h. Somite pairs were
counted after a total of 26 h in culture. Embryos cultured for 6 h
with 100 mM ethanol showed markedly delayed in vitro devel-
opment as compared with control embryos (Fig. 3). The coin-
cubation of cultured embryos with NAP or P7A-NAP signifi-
Fig. 2. Structure–activity relation for NAP protection of cortical cultures
from TTX toxicity. Cortical neuronal cultures were incubated for 4 days in the
absence (control) and presence of 1 M TTX. Peptides were added with TTX as
indicated. Shown is the mean  SEM number of neurons from three to four
determinations. The results shown were derived from two independent ex-
periments. The dotted horizontal line indicates the number of surviving
neurons in control cultures (305  10, n  5) that were not treated with TTX.
Dose–response curves are shown as follows: NAP, S5A, I6A, and P7A (A); NAP,
N1A, and V4A (B); and NAP, P3A, and Q8A (C).
Fig. 3. Effect of ethanol and NAP peptides on cultured C57BL6J gestational
day 8 mouse embryos. (A) Mean  SEM number of somite pairs in individual
embryos treated for 6 h under control conditions (n  13), in the presence of
100 mM ethanol alone (E, n  44), or with 100 mM ethanol combined with 100
pM NAP (NAPE, n  17), I6A-NAP (I6AE, n  23), or P7A-NAP (P7AE, n  28)
and after an additional 20 h of culture. ✛ , P  0.0001, compared with ethanol
alone. *, P  0.0001, compared with control. (B) Shown is a representative
embryo (median number of somites) from each of the five experimental
groups: control, 21 somites; ethanol (EtOH), 14 somites; ethanol plus NAP
(EtOHNAP), 20 somites; ethanol plus I6A-NAP (EtOHI6A), 16 somites; and
ethanol plus P7A-NAP (EtOHP7A), 18 somites.
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cantly reduced ethanol-induced growth retardation. In contrast,
treatment of cultured embryos with I6A-NAP did not signifi-
cantly reduce ethanol-induced growth retardation.
Comparison of Structure–Activity Relation for NAP Antagonism, Neu-
roprotection, and Prevention of Ethanol Embryotoxicity. The labo-
rious and costly nature of whole-embryo culture permitted the
evaluation of only a single concentration of selected NAP
mutants. To compare the efficacy of NAP mutants among three
different assay systems, we expressed the data for 100 pM
peptide as a percent of maximal NAP activity for ethanol
antagonism and neuroprotection, and as a percent of maximal
possible prevention of ethanol embryotoxicity (Fig. 4). The
activities of NAP, P7A-NAP, and I6A-NAP were remarkably
similar for ethanol antagonism and prevention of ethanol em-
bryotoxicity. In contrast, P7A-NAP had no neuroprotective
activity, but showed 56% of maximal NAP ethanol antagonism
and 53% of maximal prevention of ethanol embryotoxicity.
Discussion
NAP is a multifunctional peptide that protects neural cells
against a wide array of toxins and insults (19, 24, 25, 30, 31, 43).
This broad neuroprotective profile suggests that NAP acts
downstream of convergent cellular pathways that trigger cell
death. Therefore, NAP might prevent ethanol teratogenesis by
a general protective effect against ethanol-induced oxidative
injury or apoptosis. NAP also blocks ethanol inhibition of
L1-mediated cell–cell adhesion (32). We have speculated that
ethanol inhibition of L1 adhesion might cause anoikis, the
induction of apoptosis through loss of cell–cell contact (11). This
hypothesis suggests a second possible mechanism for NAP
prevention of ethanol teratogenesis: the upstream antagonism of
a specific action of ethanol that triggers cell death.
We undertook the present study to learn which of two actions
of NAP correlated best with NAP prevention of ethanol em-
bryotoxicity: antagonism of ethanol inhibition of L1 adhesion or
NAP’s broad neuroprotective actions. We chose to examine
NAP protection against TTX toxicity in cortical cultures, be-
cause this was the first and best established model of NAP’s
broad neuroprotective actions (18, 44). TTX blocks electrical
activity in cortical neurons, activating a process that eliminates
neurons that fail to make or sustain functional connections (40).
We used 100 mM ethanol in our experiments, because this high
concentration is observed in alcoholics (45) and reliably pro-
duces teratogenic effects in several models of FAS (4, 11, 46).
Moreover, a high concentration of ethanol provides a stringent
test of any putative ethanol antagonists.
Structure–activity analysis revealed both similarities and dif-
ferences for NAP antagonism and NAP neuroprotection. The
SIP region of NAP was crucial for both actions of NAP. This
finding is not surprising, given the conservation of the SIP region
in NAP and SAL. NAP and SAL have a similar spectrum of
neuroprotective activity, and both antagonize ethanol inhibition
of L1 adhesion (32). The N-terminal Asn of NAP was relatively
insensitive to Ala replacement, as was the C-terminal Gln. In this
respect, the structure–activity relation of NAP neuroprotection
differs from that of SAL, which was sensitive to changes in both
the N-terminal and C-terminal regions (18). The relative insen-
sitivity of NAP to N-terminal and C-terminal replacement
suggests the feasibility of adding reporter molecules to either end
of the NAP peptide to further study its mechanism of action.
The most striking difference in the structure–activity relation
between NAP antagonism and NAP neuroprotection was within
the SIP region. Ala replacement of either Ser-5 or Pro-7
abolished NAP neuroprotection but had relatively minor effects
on the efficacy of NAP antagonism. In contrast, Ala replacement
of Ile-6 caused only a small reduction in the efficacy of NAP
neuroprotection but reduced by half the efficacy of NAP an-
tagonism. The potency of NAP for ethanol antagonism was
reduced by Ala substitution at all sites except the N-terminal
Asn; however, the Ile-6 site was by far the most sensitive. The
potency of NAP for neuroprotection was reduced primarily by
Ala replacement at Asn-1, Pro-3, and within the SIP region.
Thus, the efficacy and potency of NAP for neuroprotection
depended most on Ser-5 and Pro-7, whereas the efficacy and
potency of NAP for ethanol antagonism depended most on Ile-6.
Dose–response curves also differed for NAP antagonism and
NAP neuroprotection. NAP antagonism demonstrated a broad
dose–response curve with half-maximal effects in the femtomo-
lar range (32). In contrast, NAP neuroprotection showed two
peaks of activity with half-maximal effects in the subfemtomolar
and picomolar range. The two peaks of NAP neuroprotective
activity could result from the interaction of NAP with two
different molecular targets or different states of the same target.
However, neither target appears to be the same as that which
mediates NAP antagonism, because Ala substitution for Ser-5 or
Pro-7 abolished both peaks in the neuroprotection assay, but did
not eliminate NAP antagonism. These data imply that NAP
interacts with at least two, and possibly three, distinct molecular
targets to produce neuroprotection and ethanol antagonism.
Picomolar concentrations of NAP significantly prevented
ethanol-induced growth retardation in mouse whole-embryo
culture. This finding confirms observations in a different animal
model of FAS, where fetal wastage and growth retardation at
birth were the primary outcome measures (12). Most impor-
tantly, P7A-NAP significantly reduced ethanol embryotoxicity,
whereas I6A-NAP did not. This profile of activity strongly
resembles that for NAP antagonism but differs strikingly from
that for NAP neuroprotection. Taken together, these data
indicate that NAP prevention of ethanol’s embryotoxicity
correlates better with NAP antagonism than with NAP
neuroprotection.
It is noteworthy that despite the multiplicity of mechanisms by
which ethanol disrupts fetal development, antagonists for a
single action of ethanol have such robust effects in preventing
ethanol teratogenesis. This finding suggests that ethanol disrup-
tion of L1 plays an important role in the pathogenesis of FAS.
It remains possible that as-yet-unknown actions of NAP share
Fig. 4. Relative effect of NAP mutants on ethanol antagonism, neuropro-
tection, and prevention of ethanol embryotoxicity. Data for 100 pM of the
indicated peptides were expressed as a percentage of maximal NAP effect
(ethanol antagonism, ethanol neuroprotection) or as a percentage of maxi-
mal possible prevention of ethanol embryotoxicity. L1, percentage of maximal
NAP antagonism of ethanol inhibition of L1 adhesion (see Fig. 1). TTX, per-
centage of maximal NAP protection of TTX neurotoxicity (see Fig. 2). Embryo,
percentage of peptide protection from the full reduction in somite number
caused by ethanol (see Fig. 3). A different measure was used in the whole-
embryo experiments, because it was not feasible to establish a maximal NAP
effect through a dose–response curve.

















the same structure–activity relation as NAP antagonism and are
responsible for NAP prevention of ethanol embryotoxicity.
However, this seems unlikely, given that two structurally unre-
lated molecules, NAP and 1-octanol, antagonize ethanol inhi-
bition of L1 adhesion and prevent ethanol teratogenesis (11, 12,
16, 32). At least in mouse whole-embryo culture, antagonism of
ethanol inhibition of L1 adhesion is sufficient for preventing
ethanol-induced embryotoxicity.
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